Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic oral etoposide.

F A Greco1, D H Johnson, J D Hainsworth

  • 1Division of Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.

Cancer
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis.

Alimentary pharmacology & therapeutics·2014
Same author

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

British journal of cancer·2013
Same author

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Dual-scan acquisition for accelerated continuous-wave EPR oximetry.

Journal of magnetic resonance (San Diego, Calif. : 1997)·2012
Same author

Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.

Lung cancer (Amsterdam, Netherlands)·2012
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
Same journal

Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

Cancer·2026
Same journal

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
See all related articles

Extended etoposide schedules show promise for advanced cancers. Prolonged oral etoposide administration is feasible, well-tolerated, and effective in patients with small cell lung cancer and germ cell tumors, even those resistant to standard treatments.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Etoposide is a crucial chemotherapeutic agent for advanced neoplasms like small cell lung cancer (SCLC), non-Hodgkin's lymphomas (NHL), and germ cell tumors.
  • Etoposide exhibits significant schedule dependency, with prolonged administration potentially offering superior outcomes compared to standard 3- to 5-day regimens.

Purpose of the Study:

  • To evaluate the feasibility, toxicity, and efficacy of extended administration schedules for etoposide in various advanced cancers.
  • To explore the potential of chronic oral etoposide in patients resistant to standard chemotherapy or high-dose regimens.

Main Methods:

  • Phase I and II clinical studies were conducted using prolonged etoposide administration (e.g., 21-day schedules) at doses of 50 mg/m2/day.
  • Pharmacokinetic studies assessed the bioavailability and plasma concentrations of orally administered etoposide during extended courses.

Related Experiment Videos

Main Results:

  • Extended etoposide schedules were found to be feasible with moderate toxicity.
  • Significant responses were observed in patients with SCLC, lymphoma, and germ cell tumors, including those resistant to standard etoposide-cisplatin or high-dose etoposide with bone marrow transplantation.
  • Preliminary pharmacokinetic data indicated high oral bioavailability (91%–96%) and sustained plasma concentrations above 1 microgram/ml during prolonged oral administration.

Conclusions:

  • Extended etoposide administration schedules, particularly chronic oral dosing, are a viable and effective treatment strategy for advanced cancers.
  • This approach shows promise for overcoming resistance to standard chemotherapy and may represent a novel application of etoposide with a potentially broader activity spectrum.